Wantai Biotech (603392.SH): Application for clinical trial of freeze-dried recombinant respiratory syncytial virus vaccine (CHO cells) accepted

Zhitong Finance App News, Wantai Biotech (603392.SH) issued an announcement. Recently, Xiamen Wantai Canghai Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, received the administrative license “Notice of Acceptance” from the National Drug Administration (hereinafter referred to as the “State Drug Administration”), and the “freeze-dried recombinant respiratory syncytial virus vaccine (CHO cells)” clinical trial application declared by the company has been accepted.

The application for a freeze-dried recombinant respiratory syncytial virus vaccine (CHO cell) clinical trial was accepted, which is an important step in the company's innovative vaccine development process. Focusing on the research direction of respiratory syncytial virus vaccines, the company carries out an important layout of further clinical exploration and optimization of different formulation technology paths based on existing core antigen design, recombinant protein expression and formulation development. It helps the company to systematically evaluate the immune response, safety, tolerability and promotion applicability of relevant candidate products in target groups in the early clinical stage, and provides a basis for subsequent product development path selection and clinical plan optimization.